
- Volume 0 0
APhA SUPPORTS FDA RULES FOR DUAL STATUS
Organized pharmacy leaders urged theFDA to develop new rules clarifying theagency's power to approve dual statusdrugs—a move that could clear the pathfor the simultaneous marketing of pharmaceuticalsas both prescription andOTC products.
In urging the agency to act on thisissue, officials at the American PharmacistsAssociation (APhA) cited the recentupsurge in prescription to OTC switchesand the likelihood of even more Rx drugsbeing approved for nonprescription salein the near future. "As the number ofswitch applications increases, so will thepotential for active ingredients that maybest be simultaneously classified as botha prescription and an OTC, or placed insome type of in-between or transitioncategory," an APhA official said.
Articles in this issue
almost 20 years ago
Resealable and Nultraviolet Ultraviolet (UV) Inhibitant Bagsalmost 20 years ago
High Alert Insulin Binalmost 20 years ago
Hydase (hyaluronidase injection, USP)almost 20 years ago
Humira (adalimumab)almost 20 years ago
INVANZ (ertapenem for injection)almost 20 years ago
Compounding HOTLINEalmost 20 years ago
Customer Guilty of Prescription Fraud by Supporting Friendalmost 20 years ago
Counterfeit Drugs: A Life-or-Death Problemalmost 20 years ago
Qui Tam Lawsuits Blow the Whistle on PBMsalmost 20 years ago
Can You Read These Rxs?Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.